— The world's largest tech and AI show brought groundbreaking innovations in healthcare, neurotech and life sciences to the forefront — M42, Cleveland Clinic, SandboxAQ, Mammoth Biosciences, Paradromics and Liquid AI steered the conversations on faster, more effective healthcare discoveries and industry transformation The convergence of AI, quantum computing, and biosciences is propelling the global […]

— Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours — LEU011 has been well tolerated, with disease control observed in multiple patients at lowest dose evaluated to date — Enrolment continues in dose-escalation segment of the AERIAL trial with additional data for LEU011 anticipated during the first half of 2026 — Poster

NEW YORK CITY, NY / ACCESS Newswire / November 10, 2025 / If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ:CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=176379&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

MALMÖ, SE / ACCESS Newswire / November 10, 2025 / Ascelia Pharma (STO:ACE) – Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application for its first-in-class orphan liver imaging drug Orviglance®. In line with the strategy

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of common stock of Cepton, Inc. (NASDAQ: CPTN) between July 29, 2024 and January 6, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased or sold Cepton, Inc.

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”), of the importantNovember 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokineticscommon stock during the Class Period you may

Maximize capping efficiency and minimize double-stranded RNA (“dsRNA”) in the manufacturing of self-amplifying mRNA Primrose Bio, Inc. (“Primrose”), a company with proprietary therapeutic manufacturing technologies, today announced the launch of PrimaRNApols™ExTend Cap AU, an RNA polymerase engineered to significantly improve manufacturing of self-amplifying mRNA vaccines and therapeutics. https://mma.prnewswire.com/media/2214146/Primrose_Bio_Logo.jpg ExTend Cap AU enables high-yield, fully capped

(NYSE:FCN), LONDON, Nov. 10, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it has strengthened its Tax Advisory team in the Europe, Middle East and Africa (“EMEA”) region with the addition of two senior experts. Marcus Rea joins the firm as Senior Managing Director, while Thomas Lassey has been appointed as

(Helsinki:NOKIA),(Irish:IRSH),(LSE:0HAF),(Paris:NOKIA), Press ReleaseNokia readies TNN Denmark for AI-powered 5G future Nokia signs a new four-year extension with TNN as sole supplier of 5G RAN and managed services across Denmark. Modernization leverages Nokia's energy-efficient AirScale portfolio and MantaRay solutions portfolio powered by AI and automation. Introduction of autonomous and AI-ready capabilities to enhance network performance, capacity